ARS Pharmaceuticals, Inc. (SPRY) Friday said the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for EURneffy (adrenaline nasal spray) for the emergency treatment of allergic reactions (anaphylaxis).
The formal marketing authorization of EURneffy, which is the trade name for neffy in the European Union, is expected in the third quarter of this year. The company expects to make the drug available in Europe in the fourth quarter.
The recommendation for marketing authorization is based on comprehensive data package comparing EURneffy to approved injectable products across a range of dosing scenarios as well as supportive historical data from injectable products.
The company's New Drug Application to the FDA for neffy is under review with a decision expected on October 2.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.